about
Intracranial biodegradable silica-based nimodipine drug release implant for treating vasospasm in subarachnoid hemorrhage in an experimental healthy pig and dog model.Absorption, elimination and cerebrospinal fluid concentrations of nimodipine in healthy beagle dogs receiving human intravenous and oral formulation.Nimodipine activates TrkB neurotrophin receptors and induces neuroplastic and neuroprotective signaling events in the mouse hippocampus and prefrontal cortex.Trial Readiness in Cavernous Angiomas With Symptomatic Hemorrhage (CASH).A conserved CCM complex promotes apoptosis non-autonomously by regulating zinc homeostasisComprehensive transcriptome analysis of cerebral cavernous malformation across multiple species and genotypesPlasma Biomarkers of Inflammation and Angiogenesis Predict Cerebral Cavernous Malformation Symptomatic Hemorrhage or Lesional GrowthPhenotypic characterization of murine models of cerebral cavernous malformationsEditorial for "Ensemble Learning for Early-Response Prediction of Antidepressant Treatment in Major Depressive Disorder"Phantom validation of quantitative susceptibility and dynamic contrast-enhanced permeability MR sequences across instruments and sitesRisk Factors for Recurrent Hematoma After Surgery for Acute Traumatic Subdural HematomaRho Kinase Inhibition Blunts Lesion Development and Hemorrhage in Murine Models of Aggressive Pdcd10/Ccm3 DiseaseSubclinical imaging changes in cerebral cavernous angiomas during prospective surveillanceSurgical Performance Determines Functional Outcome Benefit in the Minimally Invasive Surgery Plus Recombinant Tissue Plasminogen Activator for Intracerebral Hemorrhage Evacuation (MISTIE) ProcedureSymptomatic Brain Hemorrhages from Cavernous Angioma After Botulinum Toxin Injections, a Role of TLR/MEKK3 Mechanism? Case Report and Review of the LiteratureTranscriptome clarifies mechanisms of lesion genesis versus progression in models of Ccm3 cerebral cavernous malformationsA Brain-Targeted Orally Available ROCK2 Inhibitor Benefits Mild and Aggressive Cavernous Angioma DiseaseBiomarkers of cavernous angioma with symptomatic hemorrhageCerebral cavernous malformations form an anticoagulant vascular domain in humans and miceAtorvastatin Treatment of Cavernous Angiomas with Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) TrialPermissive microbiome characterizes human subjects with a neurovascular disease cavernous angiomaCommon transcriptome, plasma molecules, and imaging signatures in the aging brain and a Mendelian neurovascular disease, cerebral cavernous malformation
P50
Q35050830-52F9BDDE-7269-4335-B204-149D501F12AFQ41477441-BC3DECF3-CE14-4B1C-A6EA-C8BA3030E0AAQ48554814-996A7542-A8FA-421F-AF59-4C94F648471EQ52585802-FA2270E3-DFAB-477D-B3F2-4683041E58ABQ64106050-ACFDA21E-8EAF-4521-9798-F7D99E0BCD7CQ64261882-DDE56413-3295-494F-8632-5BC0C34867CAQ88547137-B370FCAE-FB8F-4871-BB51-2D5C0186B559Q89267281-41860720-7CE5-4BDA-AFBB-4E246AC250F2Q89605372-9F62148D-5F0E-4EF5-87BB-B1FEE3F7CBBEQ90085339-1DC4AEC4-D5A0-4564-A266-DB75937DB1B8Q91030452-D4B31EC6-7A86-4C7C-8F8D-F2A860F70171Q91463365-E389E78F-5A69-4669-9F3F-499EA337FFFFQ91539482-E07AF182-3E75-4254-86F4-9E313A536B4FQ92493721-19DF4A86-5952-469D-8770-B3F333741C26Q92514988-A88B1F86-B3B3-4133-9948-4968D6E9FA42Q92705381-2235FB90-E005-41AC-AFFB-4775081B82C2Q92850697-F982B28B-A1BF-44BD-A1FB-694CA375A50CQ92884386-4803E24A-11C2-4CAC-ADF1-6C893F7127D7Q93159519-10282580-3FE0-4586-A3B5-F58048D70C75Q93371239-3BDAE95A-00B4-48E6-8BF8-AAFB3D54CE1AQ95933817-D7DB1C16-6C0B-4299-9CEF-ACBFDDEA86B2Q96582168-21035895-1203-4E45-BDFC-9B47491BA9AE
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Janne Koskimäki
@en
Janne Koskimäki
@nl
type
label
Janne Koskimäki
@en
Janne Koskimäki
@nl
prefLabel
Janne Koskimäki
@en
Janne Koskimäki
@nl
P31
P496
0000-0002-2311-6327